Read MoreBlackout Round 2? Californians brace for possible outage | For toymaker Hasbro, trade wars are no fun
ap

Business News

A helicopter makes a water drop as flames threaten homes on a ridgeline as a wildfire threatens homes in the Pacific Palisades area of Los Angeles, Monday, Oct. 21, 2019. (AP Photo/Reed Saxon)
Blackout Round 2? Californians brace for possible outageHundreds of thousands of Northern California residents braced for another possible power outage as the state's largest utility warned that a return of dangerous fire weather could prompt shut-offs
The Associated Press1 hour ago
FILE- In this Nov. 9, 2018, file photo Operation made by Hasbro is displayed shelves in the expanded toy section at a Walmart Supercenter in Houston. Shares of Hasbro are plunging after the company said the trade war is hammering its supply chain. The toymaker on Tuesday reported third-quarter net income of $212.9 million, or $1.67 per share. (AP Photo/David J. Phillip, File)
For toymaker Hasbro, trade wars are no funThe trade war hits Hasbro with toy season approaching, and price hikes may be on the way for customers
The Associated Press2 hours ago
FILE - In this May 6, 2017, file photo Nike CEO and President Mark Parker talks at the finish line of a 2 hours marathon, at the Monza Formula One racetrack, Italy. Parker is stepping down early next year. He will be replaced by board member John Donahoe, who formerly ran e-commerce company eBay. (AP Photo/Luca Bruno, File)
Nike CEO Mark Parker to step down in JanuaryNike says its longtime CEO Mark Parker is stepping down in January
The Associated Press4 hours ago
FILE - In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia. The announcement Tuesday, Oct. 22, 2019, is a surprise because the company earlier this year stopped two studies of the drug, called aducanumab, after partial results suggested it was not working. (AP Photo/Matt York, File)
Biogen reanalyzes studies, presses ahead on Alzheimer's drugThe drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia
The Associated Press4 hours ago
More Business News
This component is currently unavailable.
AdChoices

Market Watch